Sun Pharmaceutical Industries announced that its wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection 100 mg Syringe (Nonproprietary name: tildrakizumab (genetical recombination), “Ilumya”) in Japan to treat plaque psoriasis in adult patients who have an inadequate response to conventional therapies.
Ilumya is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of proinflammatory cytokines and chemokines.
Junichi Nakamichi, country head, Sun Pharma Japan, said, “Ilumya is Sun Pharma’s first innovative drug to be launched in the Japanese market. We are pleased to introduce a new, safe and effective treatment option for plaque psoriasis to doctors and patients in our country. This is an important milestone for Sun Pharma as we expand our product portfolio in Japan.”